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Abstract: Breast cancer survivors suffer from disproportionate cardiovascular disease risk 
compared to age-matched controls. Beyond direct cardiotoxic effects due to treatments such as 
chemotherapy and radiation, breast-cancer-related reductions in skeletal muscle mass, quality and 
oxidative capacity may further contribute to cardiovascular disease risk in this population by 
limiting the ability to engage in aerobic exercise—a known promoter of cardiovascular health. 
Indeed, 20%–30% decreases in peak oxygen consumption are commonly observed in breast cancer 
survivors, which are indicative of exercise intolerance. Thus, breast-cancer-related skeletal muscle 
damage may reduce exercise-based opportunities for cardiovascular disease risk reduction. 
Resistance training is a potential strategy to improve skeletal muscle health in this population, 
which in turn may enhance the capacity to engage in aerobic exercise and reduce cardiovascular 
disease risk.  
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1. Introduction 
Diagnostic and therapeutic advances have drastically improved breast cancer survival rates over 
the last half-century [1,2], yet survivors suffer from disproportionate cardiovascular disease (CVD) 
risk [3,4]. Breast cancer survivors have a 1.8-fold greater risk of CVD-specific mortality compared to 
healthy controls [3], and CVD is now the leading cause of death among early-stage breast cancer 
survivors over 65 years of age [5,6]. Free radical-mediated cardiomyocyte damage and the 
subsequent impairment of central as well as peripheral cardiovascular function are associated with 
two primary cancer treatments: chemotherapy and radiation [7–12]. In the case of chemotherapeutics, 
free-radical damage causes dysregulation of sarcomeric proteins and myocyte necrosis [7,13]. Free 
radical damage resulting from radiation therapy can cause coronary vascular injury, including 
endothelial cell proliferation, intima-media thickening, lipid deposition, and adventitial fibrosis 
[11,14,15]. Ultimately, these effects can lead to, among other complications, ventricular dysfunction 
and heart failure [9–11,14,16]. Though these treatments are not used solely in breast cancer and thus 
elicit cardiotoxic effects in other cancer populations [17], these effects may be particularly harmful in 
breast cancer survivors since i) CVDs and breast cancer share risk factors (e.g., hypercholesteremia, 
hypertension, obesity) [18–20] and ii) most women are diagnosed with breast cancer after 
menopause, a period when CVD risk increases due to declining estrogen [21,22]. Additionally, many 
lifestyle factors such as physical inactivity and obesity (which may exist at the time of diagnosis, or 
develop/worsen following diagnosis and treatment) influence these shared risk factors, and may 
exacerbate cardiotoxic effects of treatments, thereby further contributing to CVD risk [23–25]. 
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Interestingly, skeletal muscle dysfunction—including reductions in mass, quality, and oxidative 
capacity—is also a side-effect of cancer treatment, and has been observed in various cancer types 
[26,27], including breast cancer [12,28]. While skeletal muscle dysfunction may be preexisting, it can 
also be a direct (e.g., anthracycline-mediated skeletal muscle damage) or indirect (e.g., atrophy as a 
result of treatment-mediated physical inactivity) consequence of traditional treatments [12,19,28–30]. 
Skeletal muscle dysfunction may be a central component linking many therapy-related toxicities and 
lifestyle factors with overall CVD risk, and is potentially a unique, additional contributor to CVD risk 
in this population [31,32]. 
The detrimental effects of breast cancer treatment and lifestyle factors on cardiovascular health 
have been evaluated using gold standard cardiopulmonary exercise testing (CPET) assessment of 
peak oxygen consumption (VO2peak) [23,33,34]. VO2peak is a global indicator of the function of the 
cardiovascular-muscular axis which facilitates the intake, transport, uptake, and utilization of 
oxygen, and is related to the capacity to perform aerobic exercise. Furthermore, VO2peak is linked to 
CVD, disability, and mortality in healthy and clinical populations, including breast cancer [35–37]. 
Dysfunctional components of the cardiovascular–muscular axis may partially mediate the association 
between VO2peak and CVD risk. It is also plausible that diminished VO2peak, an indicator of exercise 
intolerance, contributes to CVD risk by creating a barrier for engagement in cardio-protective 
behaviors such as aerobic exercise and physical activity. Of concern, breast cancer survivors typically 
have a VO2peak 20%–30% less than healthy age-matched controls [28,34,38], displaying an exercise 
intolerance that skeletal muscle dysfunction may be driving. Breast cancer-related treatment and 
lifestyle factors—which may or may not be directly related to said treatment—can lead to 
maladaptive changes in skeletal muscle mass, quality, function, and oxidative capacity [32,39,40]. 
These negative changes can contribute to reduced VO2peak and promote exercise intolerance [28,32,41]. 
Somewhat ironically, muscular health and fitness are essential to properly engage in the very 
practices known to promote cardiovascular health, specifically, exercise. Therefore, compromised 
muscle health may not only directly place an individual at risk of poor health outcomes but may also 
complicate their ability to engage in the strategies that may offer them physiological protection. 
In this short review, we discuss how breast cancer-related treatment and lifestyle factors may 
negatively impact skeletal muscle health and oxygen consumption, thereby contributing to exercise 
intolerance and, in turn, elevated CVD risk. More specifically, we describe how exercise intolerance 
as a result of breast cancer-mediated skeletal muscle damage may impede the utilization of aerobic 
exercise as a therapeutic, cardioprotective tool. Future considerations for researchers and clinicians 
are also highlighted with a particular emphasis on resistance training as a feasible strategy to combat 
the deleterious effects of muscle damage on CVD risk in this population. 
2. Skeletal Muscle Damage 
2.1. Reduced Muscle Mass 
The deleterious effects of breast cancer-related treatment and lifestyle factors can negatively 
affect skeletal muscle size, which can contribute to functional limitations, including exercise 
intolerance [12,23,28]. Decreased muscle size, fiber cross-sectional area, and myocyte size have been 
reported in a number of cancers, including breast cancer [12,39,40]. Reductions in cross-sectional area 
have been shown in single fibers for both slow-twitch myosin heavy chain and fast-twitch myosin 
heavy chain IIa fibers [39]. Moreover, these changes seem to occur independent of weight loss [39]. 
Breast cancer treatments and resulting fatigue can lead to decreased physical activity [42], which 
likely contributes to muscle wasting as a result of disuse [12,25,43]. Chemotherapeutics may directly 
confer myotoxic effects which promote myofiber atrophy [12]. Specifically, oxidant stress-induced 
AMP-activated kinase as a result of chemotherapy can suppress protein synthesis and/or increase 
proteolysis [44], yet such changes may also occur independent of reactive oxygen species [12]. 
Reduced muscle mass has been associated with decreased aerobic capacity in rodent cancer models 
[45], as well as in non-cachectic and cachectic human patients with heart failure [46,47]. Muscle 
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atrophy can decrease peripheral muscle perfusion [47], as well as promote fatigue and weakness, all 
of which can contribute to exercise intolerance [28]. 
2.2. Reduced Muscle Quality 
Breast cancer-related treatment and lifestyle factors have been associated with impaired skeletal 
muscle quality, which, in turn, may contribute to exercise intolerance [32]. The most widely 
recognized aspect of reduced skeletal muscle quality in breast cancer is cachexia, which is 
characterized by intramuscular fat deposition and sarcopenia (skeletal muscle atrophy) [12,48]. 
Anthracycline-based chemotherapeutics have been linked to deleterious changes in the 
intramuscular fat to skeletal muscle ratio [49], yet these compositional shifts are also known to occur 
as a result of poor lifestyle factors, such as physical inactivity and obesity [50,51]. Importantly, the 
ratio of intramuscular fat to skeletal muscle has been inversely associated with local muscle and 
whole-body VO2 in breast cancer survivors [32] and reported to explain approximately 50% of the 
variability in cardiorespiratory fitness in these individuals [32]. It is not fully clear how intramuscular 
fat is related to VO2, but potential mechanisms include: i) blood flow diversion to metabolically 
inactive intramuscular fat via vasodilation of adipose tissue vessels, ii) increased distance for oxygen 
to travel from capillaries to muscle mitochondria, and iii) decreased overall blood flow to tissue 
[32,52–54]. Together, these effects may limit oxygen transport, diffusion, and uptake, and thereby 
promote exercise intolerance [32,52–54]. 
2.3. Reduced Oxidative Capacity 
In addition to reductions in skeletal muscle quality and mass, diminished muscular oxidative 
capacity has been reported among breast cancer survivors [40]. Several factors may contribute to 
impaired oxidative capacity in breast cancer survivors, including direct treatment-related effects (e.g., 
mitochondrial damage associated with treatment-mediated reactive oxygen species) and indirectly 
through physical inactivity [12,28]. Peripheral changes at the level of the skeletal muscle and 
microvasculature may explain why decreased aerobic capacity has been observed despite maintained 
central cardiac function in breast cancer survivors during CPETs [23,55]. Breast cancer survivors with 
significant reductions in VO2peak may experience diminished aerobic capacity due to peripheral issues 
such as reduced capillary-fiber ratio and number of oxidative fibers, despite having a preserved 
ejection fraction [53,55]. Other potential peripheral candidates mediating the decrease in oxidative 
capacity seen in breast cancer include decreases in: i) skeletal muscle blood flow, ii) skeletal muscle 
oxygen diffusion, and iii) mitochondrial content (e.g., citrate synthase) and size including within both 
sub-sarcolemmal and intermyofibrillar compartments, potentially resulting in impaired glycolysis 
and fatty acid oxidation [12,38,40,56]. Together, breast-cancer-related reductions in microvascular 
and metabolic function within the skeletal muscle can reduce skeletal muscle oxidative capacity and 
lead to exercise intolerance. 
3. Cardiovascular and Clinical Repercussions of Skeletal Muscle Damage 
The adverse changes in skeletal muscle quality, mass, and oxidative capacity contribute to a 
range of functional consequences and negative outcomes, including decreased quality of life (QOL) 
[57], fatigue [58], arm lymphedema [59], muscle weakness [29], diminished capacity to perform 
activities of daily living [60], and poor prognosis [61]. Impairment in skeletal muscle structure and 
function have also been linked to reduced VO2peak and exercise intolerance [23], which may be the 
limitation of skeletal muscle dysfunction most tightly associated with whole-body health and CVD 
risk [31]. Dysfunctional components of the cardiovascular-muscular axis may partially mediate the 
association between VO2peak and CVD risk. However, it is also possible that VO2peak reductions and 
exercise intolerance as a result of breast cancer-related skeletal muscle damage is further contributing 
to CVD risk by creating a barrier for engagement in cardioprotective strategies such as aerobic 
exercise and physical activity. For example, leg strength has been shown to be related to both 6-min 
walk test [39], and VO2peak [41]. Further highlighting the practical implications for exercise intolerance, 
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one-third of breast cancer survivors may have a VO2peak less than 15.4 mL/kg/min—the aerobic 
capacity needed for functional dependence [38]. As such, exercise intolerance may contribute to CVD 
risk in breast cancer survivors by limiting the potential to garner cardioprotective benefits from 
exercise. Ultimately, limitations at the level of the skeletal muscle may hamper breast cancer 
survivors’ ability to i) engage in consistent aerobic exercise training, and/or ii) reach a high enough 
exercise intensity to reap cardioprotective effects [31]. 
Limited Potential for Aerobic Exercise as a Promoter of Cardiovascular Health 
Various exercise modalities have been assessed as tools to promote physiological and 
psychological health during and following treatment in many cancers [62,63]. Aerobic exercise and 
resistance training have shown benefits in a variety of cancers types—including breast cancer—with 
improvements observed in strength, QOL, physical capacity, and mortality, among others [62–65]. 
While individual factors and contraindications are important to consider, exercise has generally been 
deemed a positive psychophysiological stimulus in many cancers. Indeed, exercise guidelines in 
cancer populations, including breast cancer, largely mirror guidelines for the general population, 
which consist of a combination of aerobic exercise and resistance training [66,67]. 
Indeed, structured aerobic and resistance exercise during and following breast cancer treatment 
seems to be mostly feasible and safe [68–70]. Positive psychosocial effects include improved patient 
reported fatigue [66], QOL [66,71], anxiety [71], and self-esteem [71]. Physiological improvements 
have also been reported including increased aerobic capacity (e.g., VO2peak) [71–73], muscle strength 
[71], and body composition [74]. Aerobic exercise in particular, is an appealing therapeutic strategy 
for breast cancer survivors given i) longitudinal evidence showing strong relationships between 
physical activity levels and CVD outcomes in breast cancer survivors [75,76], and ii) the potent, 
whole-body cardioprotective effects aerobic exercise confers in healthy and clinical populations 
[77,78]. Yet, limited and mixed evidence indicates beneficial cardiovascular effects of aerobic exercise 
in breast cancer survivors beyond improvements in VO2peak (e.g., resting heart rate, systolic blood 
pressure). [79–81] The lack of evidence related to the beneficial effects on other cardiovascular 
markers may be related to limited studies, differences in treatment regimens, and non-uniform 
aerobic exercise prescriptions [19,82]. However, poor skeletal muscle health may also contribute to 
the heterogenous evidence pertaining to cardio-protective effects of aerobic exercise in breast cancer. 
As described previously, breast cancer treatment can cause damage to skeletal muscle, which 
has been measured by impairment of structure (e.g., size, quality, mitochondrial content) [12,48] and 
function (e.g., performance, strength, functionality) [29,58]. Furthermore, skeletal muscle damage is 
associated with a lower aerobic capacity in clinical populations, including breast cancer survivors 
[32,46,47]. It is plausible that skeletal muscle impairment may prevent breast cancer survivors from 
participating in aerobic exercise for a long enough duration or high enough intensity to elicit 
physiological adaptations that are protective against CVD. Therefore, poor skeletal muscle health and 
function may be a prominent link between breast cancer treatment and CVD development. As such, 
the fitness and cardiovascular decrements as a result of age, breast cancer, and breast cancer 
treatment—which already place survivors at increased risk of CVD [19,83]—are even more difficult 
to combat if muscular health also declines. Thus, breast cancer survivors are battling a “triple-edged 
sword:” i) initial CVD risk from pre-existing modifiable and non-modifiable risk factors, ii) breast 
cancer treatment-mediated acquired or accelerated CVD risk, and iii) diminished skeletal muscle 
health resulting in suboptimal ability to engage in exercise to combat CVD risk. 
Given that skeletal muscle health supports exercise and movement known to prevent CVD risk 
in healthy and clinical populations [84], we posit that skeletal muscle is an important factor for the 
prevention of CVD risk in breast cancer survivors (Figure 1). In losing the optimal health and 
capability of muscle, breast cancer survivors lose or decrease their ability to fight CVD risk through 
exercise and/or may not be able to confer enough benefit in enough time to prevent CVD 
development. Resistance training is a strategy to improve strength and muscle function for breast 
cancer survivors [85,86], which can in turn improve the ability of these individuals to engage in and 
sustain aerobic exercise—a known promoter of cardiovascular health. 
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Figure 1. Extended “Multi-Hit” Hypothesis model adapted from Lee Jones et al. (2007). CV, 
Cardiovascular; O2, Oxidative; SM, Skeletal muscle. 
4. Targeting Skeletal Muscle Health with Resistance Training 
Resistance training can mitigate decreases in muscle mass, strength, aerobic capacity (VO2peak/max) 
and overall function associated with aging [87]. Furthermore, strong relationships have been reported 
in 1-repetition maximum scores and muscle fiber area with VO2peak [88,89]. Notably, our colleagues 
demonstrated that as little as two weeks of resistance training can improve VO2peak and force 
production in post-menopausal, sedentary females—the primary demographic of breast cancer 
survivors at high CVD risk [90]. Beneficial effects of resistance training have been reported in skeletal 
muscle structure and function, as well as VO2peak, in clinical conditions including breast cancer 
[40,91,92]. As such, it is possible that resistance training in breast cancer survivors could reduce 
aerobic exercise intolerance by targeting skeletal muscle health, thereby improving the capacity to 
engage in aerobic exercise and mitigate CVD risk accrual. 
Promising preliminary evidence suggests the beneficial effects of resistance training on skeletal 
muscle health and aerobic capacity in breast cancer survivors [91,92]. The improvements in skeletal 
muscle mass and strength associated with resistance training are positive adaptations in and of 
themselves. However, we further posit that these effects may have even greater implications by 
facilitating an improved ability to engage in aerobic exercise which can positively impact CVD risk. 
However, additional research is needed to investigate several critical gaps in the literature. Most 
importantly, clarification as to whether resistance training improves CVD risk in breast cancer 
survivors is needed. Second, if resistance training does ameliorate CVD risk in this population, efforts 
should be undertaken to understand if improvements in skeletal muscle health are mediating 
cardioprotective effects by enabling engagement in more optimal (e.g., greater duration, frequency, 
intensity) aerobic exercise and/or physical activity. Further work should determine optimal 
order/timing of exercise modalities (e.g., resistance exercise prior to traditional treatment to prime 
the body for aerobic exercise or combined aerobic plus resistance training following treatment). 
5. Considerations and Recommendations 
Several final considerations should be highlighted. First, one of the greatest challenges facing 
clinicians and researchers is understanding the complex interplay of CVD risk factors in breast 
cancer. This interplay has been aptly termed the “multiple hit” hypothesis, and encompasses the 
confluence of i) direct cardiotoxic effects of breast cancer treatment, ii) indirect effects of the 
treatment-mediated development of poor lifestyle factors (e.g., fatigue/stress-mediated physical 
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inactivity or weight gain), and iii) effects of pre-existing poor lifestyle factors at the time of diagnosis. 
[24] Understanding the etiology of CVD risk factors at the level of the individual may help shape 
traditional and lifestyle-based treatment strategies. 
Secondly, great heterogeneity exists in i) CVD risk accrual (or lack thereof) following cancer 
treatment [93], and ii) cardiovascular outcomes (e.g., VO2peak, systolic blood pressure) following 
exercise-based therapies in clinical populations including cancer [19,82,94]. It will be challenging, but 
necessary, to begin to understand how and why different individuals respond uniquely to various 
therapies. In particular, the prospect of being able to identify “responders” versus “non-responders” 
may influence treatment strategies and assist in more accurate prognoses. 
As alluded to previously, it will also be very difficult to determine or predict the most effective 
timing, order, and modality of exercise treatments relative to traditional treatments for optimizing 
patient health. For example, whether pre-treatment (e.g., chemotherapy, radiation) resistance 
training to “prime” skeletal muscles for aerobic work, followed by combined aerobic exercise and 
resistance training after traditional treatment is more advantageous than, say, combined exercise 
before and after traditional treatments remains an intriguing question. While tempting to speculate, 
there is likely not a “right” answer, per se. Rather, baseline characteristics (e.g., muscle strength, 
aerobic capacity), prior exercise history, pre-existing risk factors, cancer stage, traditional treatment 
plan/stage/dose, and symptom presentation following traditional treatment should weigh into 
individualized, and, ideally, supervised, exercise prescriptions [95]. For instance, resistance training 
may be the most advantageous exercise strategy to elicit high-intensity cardiac stimuli in highly 
deconditioned breast cancer survivors during adjunctive therapy [96]. The myriad factors that should 
inform exercise prescription in breast cancer survivors also highlights the need for regular interaction 
and coordination between oncologists and clinical exercise physiologists. 
6. Conclusions 
In conjunction with improved survival rates, breast cancer survivors are at increased risk of 
CVDs, including left ventricular dysfunction and heart failure [1,3,9,10]. The direct cardiotoxic effects 
of traditional breast cancer treatments, coupled with the indirect effects of treatment-mediated and/or 
pre-existing poor lifestyle factors (e.g. physical inactivity), promote elevated CVD risk [24]. Beyond 
breast cancer treatment-related central cardiac dysfunction, peripheral dysfunction at the level of the 
skeletal muscle may also contribute to CVD risk [12,61]. Specifically, decrements in skeletal muscle 
quality, mass, and oxidative capacity can contribute to exercise intolerance [23], which is tightly 
linked to CVD risk and whole-body health. [35–37]. Exercise intolerance limits opportunities for 
aerobic exercise to be used as a cardio-protective behavior in this population. Resistance training is a 
promising strategy to offset the negative effects of breast-cancer-related skeletal muscle dysfunction 
[91]. Further research is needed to i) elucidate the mechanisms by which breast-cancer treatments 
and lifestyle factors impact skeletal muscle health and ii) how skeletal muscle dysfunction may 
contribute to exercise intolerance, CVD risk, and whole-body health. 
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